Leukemia and Lymphoma

The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.

Latest News

Hodgkin lymphoma | Image credit: Dr_Microbe - stock.adobe.com
BrECADD Regimen Reaches “Unprecedently High” PFS for Patients With Hodgkin Lymphoma

June 18th 2024

The treatment regimen not only significantly improved progression-free survival (PFS) for patients with advanced stage classic Hodgkin lymphoma but was also better tolerated compared with a 20-year-old regimen being used.

FDA Approved - chrisdorney - stock.adobe.com.jpg
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma

March 7th 2024

Red Blood Cells - Design Cells stock.adobe.com
alloHSCT Yields Benefits in R/R AML Regardless of Leukemia Burden

December 22nd 2023

Highlights from ASH 2023
ICYMI: Highlights From ASH 2023

December 20th 2023

Zanubrutinib rendering | Image credit: molekuul.be - stock.adobe.com
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

December 11th 2023

Continuing Medical Education
View All
July 27th 2024

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
July 27th 2024

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

More News

Money and pills
June 10th 2023

Health Economics Implications of Hematology Therapies Spotlighted Among EHA Research

Christina Mattina
With the number of treatment options in hematology and oncology rapidly expanding, so too are the strategies for determining and ensuring cost-effectiveness, according to session speakers at the European Hematology Association (EHA) 2023 Congress.
Improving Access to Treatment Remains a Challenge in AML, Says Dr Jeffrey Lancet
June 9th 2023

Improving Access to Treatment Remains a Challenge in AML, Says Dr Jeffrey Lancet

Rose McNulty
Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Real-world data
June 9th 2023

Experts Spar Over Role of Real-World Data as Replacement for Clinical Trials in Hematology

Christina Mattina
A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.
Dr Jeffrey Lancet Discusses Best Practices for Treating AML
June 1st 2023

Dr Jeffrey Lancet Discusses Best Practices for Treating AML

Rose McNulty
Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center in Tampa, Florida, gave his insight on the treatment of acute myeloid leukemia (AML) across patient groups.
leukemia: © greenapple78 - stock.adobe.com
May 31st 2023

Puerto Ricans Have Lower Leukemia Risk, but Not in All Subtypes

Jared Kaltwasser
In some cases, individuals of Puerto Rican descent face lower risk than other Hispanic groups in the United States.
Chronic lymphocytic leukemia: © momius - stock.adobe.com
May 22nd 2023

Early Studies Show Some Patients With Richter Transformation of CLL Respond to Zanubrutinib

Jared Kaltwasser
Two studies, one of zanubrutinib alone and one that combined the therapy with tislelizumab, showed promising results in a subset of patients.
Watch-and-Wait Approach May Distress Some Patients With Hematological Cancers
May 19th 2023

Watch-and-Wait Approach May Distress Some Patients With Hematological Cancers

Rose McNulty
A recent study suggests that monitoring anxiety and distress levels during watch-and-wait disease management time frames may improve the patient experience.
FCS logo
May 10th 2023

Florida Cancer Specialists Highlights Role in Development of Polatuzumab Vedotin Plus R-CHP in DLBCL

AJMC Staff
Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.
China Approves Zanubrutinib in Treatment-Naïve CLL/SLL and Waldenström Macroglobulinemia
May 9th 2023

China Approves Zanubrutinib in Treatment-Naïve CLL/SLL and Waldenström Macroglobulinemia

Chris Ryan
China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in untreated adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.
Dr Jeffrey Lancet on the Balance Between Cost and High Quality Care in AML
May 6th 2023

Dr Jeffrey Lancet on the Balance Between Cost and High Quality Care in AML

Rose McNulty
Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, discussed the issue of cost and optimizing patient outcomes acute myeloid leukemia (AML).
Jeffrey E. Lancet, MD
May 4th 2023

Dr Jeffrey Lancet Discusses the Evolving Therapy Landscape of AML

Rose McNulty
Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.
Daiichi-Sankyo
April 24th 2023

FDA Extends Review Period for Quizartinib for Adults With FLT3-ITD–Positive AML

Mary Caffrey
Daiichi Sankyo announced that the new deadline for review of the application is July 24, 2023.
FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL
April 20th 2023

FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

Kristi Rosa
The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.
Young doctor visiting elderly woman at home: © Pixel-Shot - stock.adobe.com
April 15th 2023

Physical Activity Improves Quality of Life, Fitness Among Older Adults With CLL

Gianna Melillo
Researchers collected physical function measures and blood samples from 24 patients enrolled in a 16-week trial of at-home aerobic and/or resistance exercise.
NCCN logo
April 12th 2023

NCCN Session Offers Considerations for Frontline, Second-line Treatment Choices in CLL

Mary Caffrey
An April 1 session at the 2023 National Comprehensive Cancer Network (NCCN) on updates in CLL/SLL featured results on the ALPINE study, which led to the January 2023 approval of zanubrutinib in the frontline setting.
art rendering of diverse people
April 7th 2023

Program Cut Cancer Diagnostic Time by Over 62% for Underserved Populations

Justina Petrullo
Colocating cancer diagnostic services in in community health centers serving historically marginalized populations resulted in reduced time to a diagnosis.
Image of the words "Chronic lymphocytic leukemia": © momius - stock.adobe.com
March 27th 2023

Challenges in Standardizing Use of MRD Assessment in CLL

Jaime Rosenberg
Although minimal residual disease (MRD) has emerged as a valuable prognostic marker across several hematological malignancies, its use in chronic lymphocytic leukemia (CLL) is mostly limited to clinical trials.
Gut Microbiome May Impact CAR T-Cell Therapy Response in Patients With Lymphoma
March 17th 2023

Gut Microbiome May Impact CAR T-Cell Therapy Response in Patients With Lymphoma

Rose McNulty
A recent study found that microbiome-based biomarkers may be useful in predicting patient responses to CAR T-cell therapy for non-Hodgkin lymphoma.
Even Oncologists Sold on Value-Based Care Hesitate to Embrace the EOM
March 10th 2023

Even Oncologists Sold on Value-Based Care Hesitate to Embrace the EOM

Members of the Association of Community Cancer Centers (ACCC) Alternative Payment Coalition discussed strategies for succeeding in value-based care and voiced concerns surrounding the upcoming Enhancing Oncology Model (EOM) during a panel discussion at the ACCC 2023 Annual Meeting and Business Summit.
Dr Lee Greenberger, PhD
March 7th 2023

Dr Lee Greenberger Discusses the Pandemic's Impact on Clinical Trials in Leukemia, Lymphoma

Hayden E. Klein Rose McNulty
Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses how the pandemic changed clinical trial enrollment in the leukemia/lymphoma space.
Study Shows Survival Disparities Among Children With ALL Living in US-Mexico Border Regions
March 4th 2023

Study Shows Survival Disparities Among Children With ALL Living in US-Mexico Border Regions

Rose McNulty
Children with acute lymphoblastic leukemia living in US-Mexico border regions had worse 5-year survival rates compared with children living in other parts of Texas, a recent study found.
Dr Lee Greenberger
March 2nd 2023

What Patients With Leukemia and Lymphoma Usually Ask About COVID-19 Vaccinations

Hayden E. Klein Rose McNulty
Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses common questions that patients with leukemia and lymphoma ask about COVID-19 and vaccination.
Dr Lee Greenberger on Using Social Media to Grow a Leukemia and Lymphoma Registry
February 25th 2023

Dr Lee Greenberger on Using Social Media to Grow a Leukemia and Lymphoma Registry

Hayden E. Klein Rose McNulty
In this interview, Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses key takeaways from using social media to grow a leukemia and lymphoma registry.
BTKis in the Value-Based Care Models
February 22nd 2023

BTKis in the Value-Based Care Models

Roy Beveridge, MD, and Brian Koffman, MD, explore how the Bruton tyrosine kinase inhibitors (BTKi) fit into value-based care models for oncology and the patient support offered to aid patients in gaining access to BTKis.
Financial Burdens of BTKi Therapy
February 22nd 2023

Financial Burdens of BTKi Therapy

Brian Koffman, MD, and Roy Beveridge, MD, discuss the financial burdens of Bruton tyrosine kinase inhibitor therapy and considerations for oral therapy vs infusion therapy.
FDA logo
February 21st 2023

Recent FDA Actions: February 2023

Mary Caffrey Laura Joszt, MA
Resistance to BTKi Therapy
February 15th 2023

Resistance to BTKi Therapy

Callie Coombs, MD, reviews how patients develop resistance to Bruton Tyrosine Kinase inhibitor (BTKi) therapy and how BTKi resistance is managed.
Managing BTKis for Coverage
February 15th 2023

Managing BTKis for Coverage

Roy Beveridge, MD, discusses how payers and health systems are managing Bruton tyrosine kinase inhibitors and how they are chosen for formulary and pathway coverage.
Ponatinib Demonstrates Increased Efficacy vs Imatinib in Patients With Ph+ALL
February 14th 2023

Ponatinib Demonstrates Increased Efficacy vs Imatinib in Patients With Ph+ALL

Rose McNulty
The phase 3 PhALLCON study found ponatinib plus chemotherapy more effective than imatinib with chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leukemia cells and blood samples
February 9th 2023

Allo-HCT Not Linked With Better OS vs Consolidation Chemotherapy in AML Patients in Complete Remission

Rose McNulty
While treatment with allogeneic hematopoietic cell transplantation (allo-HCT) showed improved disease-free survival compared with conventional consolidation chemotherapy, the findings suggest there may not be an overall survival (OS) benefit with allo-HCT for patients with intermediate-risk acute myeloid leukemia (AML) during first complete remission.
<12345678
...
19>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo